One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
1625 articles with Amgen
Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted
This biotech could potentially be a better value.
Amgen Release: Results From Phase III XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85-1.14).
The PhRMA held its board meeting today, officially welcoming three new elected officers
Amgen reported its fourth-quarter financials yesterday, but in anticipation of this year's hot merger-and-acquisition market, a lot of focus has been on the company's considerable available cash.
Amgen is expected to add 220 jobs to the local economy and employ up to 300 full-time employees.
For the fourth quarter, total revenues decreased 3 percent versus the fourth quarter of 2016 to $5.8 billion.
Amgen's Parsabiv Starts to Gain Ground in US Dialysis Market with the Nephrology User Base Expected to Climb from 20% to Over 80% Within the Next Six Months
As of January 2018, Parsabiv has a J-code and the scramble to develop protocols for use has begun.
Amgen Receives CHMP Positive Opinion to Add Updated Overall Survival Data To KYPROLIS (carfilzomib) Label
The ENDEAVOR trial demonstrated that Kd reduced the risk of death by 21 percent and increased OS by 7.6 months versus Vd in patients with relapsed or refractory multiple myeloma.
Amgen today announced that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018, after the close of the U.S. financial markets.
This is a market like the world has never seen.
The biotech giant employs about 20,000 people worldwide.
In the study, 246 patients were randomized to receive Aimovig or placebo over a 12-week treatment phase.
European Commission Approves Amgen and Allergan's Mvasi (Biosimilar Bevacizumab) for the Treatment of Certain Types of Cancer
The EC approved MVASI based on a comprehensive data package that demonstrated MVASI and bevacizumab are highly similar, with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products.
Overall Survival Analysis From Amgen's KYPROLIS (Carfilzomib) Phase III ASPIRE Trial Published in the Journal of Clinical Oncology
Amgen today announced that the Journal of Clinical Oncology published positive overall survival findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone reduced the risk of death by 21 percent versus lenalidomide and dexamethasone alone and extended OS by 7.9 months in patients with relapsed or refractory multiple myeloma.
Data added to the label demonstrated that KYPROLIS and dexamethasone (Kd) reduced the risk of death by 21 percent and increased OS by 7.6 months versus Velcade (bortezomib) and dexamethasone (Vd).
1/17/2018Despite some safety concerns such as severe diarrhea, the FDA approved Puma's breast cancer drug Nerlynx in July 2017.
Amgen's migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
BC Platforms to Provide Big Data Driven Research Solutions to Amgen in Cardiovascular Diseases and Oncology
BC Platforms today announces that Amgen Finland will be using its technology solutions and research platform, including BCRQUEST.COM.
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.